PATENT APPL

Inventor(s): Appln. No.:	ANDERSON et al. 08	921,060						
	Series Code ↑	Serial No.	IED OIP					
Filed: Aug	ust 29, 1997 R	ECFI	12000					
Hon. Commis	sioner of Patents	_	2002					
Washington,	D.C. 20231	JUN 19	2002 JUN 1 1 2002					
			12 . 27					
Sir:		STATE	R 1600 2900					
REPLY/AMENDUEN CLEATER								

Group Art Unit

1644

M#

R. Schwadron

Examiner: Atty. Dkt.

0275463

1992-30-0029CP2 Client Ref

Appln. Title:

Therapeutic Application of Chimeric and Radiolabeled Antibodies to Human B Lymphocyte Restricted Differentiation

Antigen for Treatment of B Cell

Lymphoma

June 11, 2002 Date:

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

2. Total Effective Claims	1. Small Entity claim A. ⊠ NOT made B. ☐ Withdrawn C. ☐ made herewith D. ☐ made previously For B & C See Required Separate Paper (Pat-256)	Claims remaining after amendment	Highest number previously paid for		Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
3. Independent Claims	2 Total Effective Claims		**minus	20	0	x \$18/\$9 =	+ \$0	103/203
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)					0	x \$84/\$42 =	+ \$0	102/202
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached (2 mos) (3 mos) (23 mos)	4. If amendment enters proper mult	+ \$280/\$140 =	+ \$0	104/204				
date to cover the date this response is filed for which the (2 mos) requisite fee is attached (3 mos) (Usable only for ≤ 2mo.OA 4 mos) (Usable only for 30 day/1mo.OA 5 mos) \$1,440/\$720= \$1,440/\$720= \$1,960/\$980= 7. Enter any previous extension fee paid since above original due date and subtract								
8.	date to cover the date this response requisite fee is attached (Usa	+ \$110		116/216 117/217 118/218				
8.	7 Enter any previous extension fee	- \$0	W. Johnson					
9. If Terminal Disclaimer attached, add Rule 20(d) official fee		Extension Fee	+ \$110	ai sakerijk				
10. If IDS attached requires Official Fee under Rule 97 (c), add +\$180 +\$0 126 1		+ \$110/\$55	+ \$0	148/248				
11. After-Final Request Fee per rules 129(a) and 17(r)	10. If IDS attached requires Official	1 '	+ \$0					
12. No. of additional inventions for examination per Rule 129(b)	11 After-Final Request Fee per rules 129(a) and 17(r)					+ \$740/370	+ \$0	146/246
13. Request for Continued Examination (RCE) +\$740/370 +\$0 1179/1275 14. Petition fee for +\$0 15. TOTAL FEE = 16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0". 17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space. 18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space. Our Deposit Account No. 03-3975) (Our Order No. 037003 0275463 C# M#		x \$740/370 ea	+ \$0	149/249				
14. Petition fee for +\$0 15.	13. Request for Continued Examina	+ \$740/370		1179/1279				
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0". 17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space. 18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space. Our Deposit Account No. 03-3975) (Our Order No. 037003 0275463 C# M#	1	+ \$0						
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space. 18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space. Our Deposit Account No. 03-3975) (Our Order No. 037003 0275463	15.	\$110						
Our Deposit Account No. 03-3975) (Our Order No. <u>037003</u> <u>0275463</u>	16. *If the entry in this space is less than en 17. **If the "Highest number previously pa	1						
CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing of histinician rec(s) filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or	CHARGE STATEMENT: The Commissioner is	hereby authorized to C	harce any fee spe	Ou (Ou	r Deposit Account ur Order No03	7003 027546 C# M# any missing or insufficient	fee(s) filed, or ass	erted to be

duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP Intellectual Property Group

Samir Elamrani By Atty: 1600 Tysons Boulevard

Sig:

43601 Reg. No.

(703) 905-2500

(703) 905-2064

Atty/Sec: SE/AF

McLean, VA 22102

Tel: (703) 905-2000

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments

2 Hoftmins

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson et al.

Group Art Unit: 1644

Application Serial No. 08/921,060

Examiner: R. Schwadron

Filed: August 29, 1997

Title: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B

LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL

LYMPHOMA

JUN 1 1 2002

REPLY AND AMENDMENT PURSUANT TO 37 C.F.R. §1.116

HECENEO
JUN 1 9 2002

Hon. Commissioner of Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

In response to the Office Action [final rejection] dated February 11, 2002, please amend the above-identified application as follows.

06/14/2002 TGEDAHU1 00000006 033975 08

01 FC:115

110.00 CH

IN THE CLAIMS

Please cancel claims 14 and 15 without prejudice.

Please enter the following amended claims:

- 11. (Amended) A method of treating a human patient suffering from B-cell lymphoma comprising the following steps:
- (i) administration of a non-radiolabeled chimeric anti-CD20 antibody which itself when administered at a dosage of 0.4 mg/kg body weight results in nearly complete peripheral B-cell depletion within about 24 hours post treatment infusion; and
 - (ii) administration of at least one chemotherapeutic agent.
- 16. (Amended) A method of treating a human patient suffering from B cell lymphoma comprising the following steps:
 - (i) administration of a non-radiolabeled chimeric anti-CD20 antibody which itself when administered at any dosage between 0.4 to 20.0 mg/kg body weight results in nearly complete peripheral B cell depletion within about 24 hours post treatment infusion; and
 - (ii) administration of at least one chemotherapeutic agent.